Patient Advocate's Notes From 8th International Kidney Cancer Symposium
Conclusions on Optimal Systemic Control For High Risk Patients:
- Anti-angiogenic agents are capable of reducing primary tumors, but not consistently.
- There is no evidence that anti-angiogenic agents are anti-metastatic
- Monitoring tools/markers need to be developed that can measure efficacy of anti-metastatic drugs
AS a patient advocate I point out that in the summary table of neoadjuvant trials results for local control: There is a learning curve to use these drugs safely and effectively. The current neoadjuvant therapy approaches were safe in the hands of experienced clinicians... an ex...
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news
Hematology and Oncology: Images in Clinical Medicine
Editor: V. Dimov, M.D., Assistant Professor at University of ChicagoDisseminated Cryptococcosis in a CLL patient. NEJM, 05/2014.Leukemia cutis. Lancet, 10/2012.Biliary ileus. Lancet, 07/2012.Corneal snowflakes due to IgG-kappa multiple myeloma. Lancet, 08/2012.Splenic Spirals due to hepatoblastoma. NEJM, 06/2012.Hypertrophic Pulmonary Osteoarthropathy and Tripe Palms due to lung cancer. NEJM, 01/2012.Metastasis of Renal-Cell Carcinoma. NEJM, 10/2011.Amelanotic choroidal melanoma. Lancet, 03/2011.Retroperitoneal liposarcoma with lamellar bone inside.A painful cranial bulge. Lancet, 05/2011.Splenic Calcification in sick...
Source: Clinical Cases and Images - August 22, 2009 Category: General Medicine Tags: Hematology Images Oncology Source Type: news
